Indivior PLC

Legal Proceedings Report • Nov 20, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9478H

Indivior PLC

20 November 2018

INDIVIOR MAKES STATEMENT ON COURT DECISION

"Indivior is disappointed that the U.S. Court of Appeals for the Federal Circuit has vacated the preliminary injunction against Dr. Reddy's Laboratories ("DRL"). Indivior will continue to vigorously pursue ongoing infringement cases against DRL to protect its SUBOXONE® (buprenorphine and naloxone) Sublingual Film patent portfolio.

The Company is in the process of interpreting the ruling in its entirety and will issue a statement on its implications once this review has been completed."

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCLLFFELELIFIT